Skip to content

Study · In vitro (cells) · murine · 2014

3 results

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.

Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V and 4 more

Show all authors

Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB

Annals of clinical and laboratory science1 Jan 2014Cited by 14 (Europe PMC)

PMID25117093 (opens in a new tab)PepBankPUB-25117093
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In K562 leukemia cells, PNC‑27 colocalized with membrane HDM-2.

    In plain wordsIn cells from a leukemia line, PNC‑27 was found with HDM-2 in cell membranes.

    Peptide
    PNC-27
    Outcome
    Not applicableMembrane HDM-2 colocalization
    Study

    humann: not reported in source

    p53-null K562 leukemia cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that K562 cells strongly express HDM-2 protein in their membranes and that PNC-27 co-localizes with this protein in the membranes of these cells.
    1 context sentence
    Summary · context
    The anti-cancer activity and mechanism of PNC-27, which carries a p53 aa12-26-leader sequence connected on its carboxyl terminal end to a trans-membrane-penetrating sequence or membrane residency peptide (MRP), was studied against p53-null K562 leukemia cells.
  2. 02LabIn vitro (cells)Activity measurement

    In K562 leukemia cells, PNC‑27 induced nearly complete killing with LDH release, unlike PNC-29.

    In plain wordsIn cells from a leukemia line, PNC‑27 killed nearly all cells, unlike PNC-29.

    Peptide
    PNC-27
    Outcome
    IncreaseK562 cell killing
    Study

    humann: not reported in source

    p53-null K562 leukemia cells
    Comparator
    PNC-29
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Cell killing
    ≈ 100 percent
    K562 cells

    Source sentences

    Summary
    PNC-27, but not the negative control peptide PNC-29, is selectively cytotoxic to K562 cells, inducing nearly 100 percent cell killing with LDH release.
    1 context sentence
    Summary · context
    The anti-cancer activity and mechanism of PNC-27, which carries a p53 aa12-26-leader sequence connected on its carboxyl terminal end to a trans-membrane-penetrating sequence or membrane residency peptide (MRP), was studied against p53-null K562 leukemia cells.
  3. 03LabIn vitro (cells)Safety outcome

    In murine lymphocyte control cells, PNC‑27 had no effect on viability.

    In plain wordsIn cells used as normal lymphocyte controls, PNC‑27 did not kill cells.

    Peptide
    PNC-27
    Outcome
    No significant changeControl lymphocyte viability
    Study

    murinen: not reported in source

    lymphocyte control cells
    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, this peptide had no effect on the lymphocyte control cells.
    2 context sentences
    Summary · context
    Murine leukocytes were used as a non-cancer cell control.
    Summary · context
    The anti-cancer activity and mechanism of PNC-27, which carries a p53 aa12-26-leader sequence connected on its carboxyl terminal end to a trans-membrane-penetrating sequence or membrane residency peptide (MRP), was studied against p53-null K562 leukemia cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.